Mycobacterium tuberculosis Next-Generation Whole Genome Sequencing: Opportunities and Challenges

Table 3

Summary of the percentage phenotypic resistance that can be explained by genetic mutations at the locus of interest.

Drug	Locus	Percentage resistance accounted for by mutations	References
Rifampicin	rpoB	96%	[28]
Isoniazid	katG, inhA, ahpC-oxyR	84%	[29]
Ethambutol	embB	70%	[30]
Streptomycin	rrs, rpsL	60%-70%	[28]
Pyrazinamide	pncA	72%-99%	[31]
Fluoroquinolones	gyrA		[32]
		87% (Moxifloxacin)
		83% (Ofloxacin)
Aminoglycosides	rrs		[33]
		70%-80% (Capreomycin and Amikacin)
		60% (Kanamycin)